1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2013

Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2013” provides data on the Obio Pharmaceutical Holdings Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Obio Pharmaceutical Holdings Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Obio Pharmaceutical Holdings Limited and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Obio Pharmaceutical Holdings Limited - Brief Obio Pharmaceutical Holdings Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Obio Pharmaceutical Holdings Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Obio Pharmaceutical Holdings Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Obio Pharmaceutical Holdings Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Obio Pharmaceutical Holdings Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Obio Pharmaceutical Holdings Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Obio Pharmaceutical Holdings Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Obio Pharmaceutical Holdings Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Obio Pharmaceutical Holdings Limited and identify potential opportunities in those areas.

Table Of Contents

Obio Pharmaceutical Holdings Limited - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Obio Pharmaceutical Holdings Limited Snapshot 4
Obio Pharmaceutical Holdings Limited Overview 4
Key Information 4
Key Facts 4
Obio Pharmaceutical Holdings Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Obio Pharmaceutical Holdings Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Obio Pharmaceutical Holdings Limited - Pipeline Products Glance 9
Obio Pharmaceutical Holdings Limited - Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Obio Pharmaceutical Holdings Limited - Drug Profiles 10
AK-20 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
DC-9703 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
KP-624 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
KP-9928 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
PK-236 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
TG-21 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Obio Pharmaceutical Holdings Limited - Pipeline Analysis 16
Obio Pharmaceutical Holdings Limited - Pipeline Products by Therapeutic Class 16
Obio Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 18
Obio Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action 19
Obio Pharmaceutical Holdings Limited - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables


Obio Pharmaceutical Holdings Limited, Key Information 4
Obio Pharmaceutical Holdings Limited, Key Facts 4
Obio Pharmaceutical Holdings Limited - Pipeline by Indication, 2013 6
Obio Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2013 7
Obio Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2013 8
Obio Pharmaceutical Holdings Limited - Pre-Clinical, 2013 9
Obio Pharmaceutical Holdings Limited - Pipeline By Therapeutic Class, 2013 17
Obio Pharmaceutical Holdings Limited - Pipeline By Route of Administration, 2013 18
Obio Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action, 2013 19

List of Figures


Obio Pharmaceutical Holdings Limited - Pipeline by Indication, 2013 6
Obio Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2013 7
Obio Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2013 8
Obio Pharmaceutical Holdings Limited - Pipeline By Therapeutic Class, 2013 16
Obio Pharmaceutical Holdings Limited - Pipeline By Route of Administration, 2013 18
Obio Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.